Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 112Lymphoma 66Lymphoma, Large B-Cell, Diffuse 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 31Lymphoma, Non-Hodgkin 29Lymphoma, Follicular 22Burkitt Lymphoma 22Multiple Myeloma 19Leukemia 16Hodgkin Disease 16Neoplasms 14Neoplasm Metastasis 13Lymphoma, B-Cell 13Lymphoma, Mantle-Cell 11Lymphoma, Large-Cell, Anaplastic 11Lymphoma, T-Cell 8Lymphoma, B-Cell, Marginal Zone 8Lymphoma, T-Cell, Peripheral 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Hematologic Neoplasms 5Waldenstrom Macroglobulinemia 4Recurrence 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, AIDS-Related 4Immunoblastic Lymphadenopathy 4Prostate Cancer Metastatic 3Primary Myelofibrosis 3Polycythemia Vera 3Plasmablastic Lymphoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3

Interventions

dactolisib 1Prednisone 1Denosumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Castrate-resistant Prostate Cancer × Prednisone × Clear all
NCT01717898 2018-03-27

A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer

University of California, San Francisco

Phase 1/2 Terminated
6 enrolled 5 charts
Genitourinary

Castrate-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡